Načítá se...
Cabozantinib for the treatment of kidney cancer
INTRODUCTION: Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy. AREAS COVERE...
Uloženo v:
| Vydáno v: | Expert Rev Anticancer Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166873/ https://ncbi.nlm.nih.gov/pubmed/28633552 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14737140.2017.1344553 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|